AR070648A1 - Derivados de bencimidazol sustituido - Google Patents

Derivados de bencimidazol sustituido

Info

Publication number
AR070648A1
AR070648A1 ARP080103690A ARP080103690A AR070648A1 AR 070648 A1 AR070648 A1 AR 070648A1 AR P080103690 A ARP080103690 A AR P080103690A AR P080103690 A ARP080103690 A AR P080103690A AR 070648 A1 AR070648 A1 AR 070648A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
cycloalkyl
heterocyclyl
alkoxy
fluor
Prior art date
Application number
ARP080103690A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR070648A1 publication Critical patent/AR070648A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Estos compuestos se fijan sobre el FXR y pueden utilizarse como medicamentos. Reivindicacion 1: Compuestos de la formula (1) en la que X es -O-, -S-, -S(O)-, -S(O2)-, -C(R11R12)- o -C(R11R12)-C(O)O-; R1 es alquilo inferior, cicloalquilo, cicloalquil-alquilo inferior, heterociclilo o heterociclil-alquilo inferior, dichos alquilo inferior, cicloalquilo o heterociclilo pueden estar opcionalmente sustituidos por 1-4 sustituyentes elegidos con independencia entre el grupo formado por halogeno, alquilo inferior, alcoxi inferior, fluor-alquilo inferior y fluor-alcoxi inferior; R2 es hidrogeno o alquilo inferior; R3 es cicloalquilo, cicloalquil-alquilo inferior, heterociclilo o heterociclil-alquilo inferior, dichos cicloalquilo o heterociclilo pueden estar opcionalmente sustituidos por 1-4 sustituyentes elegidos con independencia entre el grupo formado por halogeno, alquilo inferior, alcoxi inferior, fluor-alquilo inferior y fluor-alcoxi inferior; R4 es alquilo inferior, cicloalquilo, cicloalquil-alquilo inferior, arilo, aril-alquilo inferior, heteroarilo, heteroaril-alquilo inferior, heterociclilo o heterociclil-alquilo inferior, dichos alquilo inferior, cicloalquilo, arilo, heteroarilo o heterociclilo pueden estar opcionalmente sustituidos por 1-4 sustituyentes elegidos con independencia entre el grupo formado por halogeno, hidroxi, alquilo inferior, hidroxi-alquilo inferior, alquilo inferior-O-alquilo inferior-O-alquilo inferior, fluor-alquilo inferior, alquilo inferior-carbonilo, alcoxi inferior, fluor-alcoxi inferior y dioxoalquileno inferior; R5, R6, R7 y R8 con independencia entre sí son hidrogeno, halogeno, alquilo inferior, alcoxi inferior, fluor-alquilo inferior, fluor-alcoxi inferior, cicloalquil-oxi o heterociclil-oxi; R9 y R10 con independencia entre sí son hidrogeno o alquilo inferior, o R9 y R10 se unen entre sí para formar un cicloalquilo o heterociclilo junto con el átomo de carbono al que están unidos; R11 y R12 con independencia entre sí son hidrogeno o alquilo inferior, o R11 y R12 se unen entre sí para formar un cicloalquilo o heterociclilo junto con el átomo de carbono al que están unidos; y las sales y ésteres farmacéuticamente aceptables de los mismos.
ARP080103690A 2007-08-27 2008-08-25 Derivados de bencimidazol sustituido AR070648A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07115005 2007-08-27

Publications (1)

Publication Number Publication Date
AR070648A1 true AR070648A1 (es) 2010-04-28

Family

ID=39967744

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103690A AR070648A1 (es) 2007-08-27 2008-08-25 Derivados de bencimidazol sustituido

Country Status (15)

Country Link
US (1) US7790904B2 (es)
EP (1) EP2188263B1 (es)
JP (1) JP5204232B2 (es)
KR (1) KR101237577B1 (es)
CN (1) CN102083799B (es)
AR (1) AR070648A1 (es)
AU (1) AU2008291148B2 (es)
BR (1) BRPI0815696A2 (es)
CA (1) CA2697167C (es)
CL (1) CL2008002506A1 (es)
ES (1) ES2387230T3 (es)
MX (1) MX2010002341A (es)
PE (1) PE20090622A1 (es)
TW (1) TW200916099A (es)
WO (1) WO2009027264A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5222953B2 (ja) * 2007-11-15 2013-06-26 エフ．ホフマン−ラ ロシュ アーゲー ベンゾイミダゾール誘導体及びｆｘｒアゴニストとしてのその使用
KR20110052741A (ko) * 2008-09-11 2011-05-18 에프. 호프만-라 로슈 아게 신규한 벤즈이미다졸 유도체
US8309581B2 (en) * 2009-09-29 2012-11-13 Hoffmann-La Roche Inc. Benzimidazole derivatives
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
JP6366721B2 (ja) 2013-09-11 2018-08-01 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｂ型肝炎ウイルス感染症を処置するための方法及び医薬組成物
CN106632065B (zh) * 2016-12-06 2019-08-30 沈阳药科大学 苯并咪唑类化合物及其应用
CN106905241B (zh) * 2017-02-14 2020-03-17 沈阳药科大学 1,2-二取代苯并咪唑衍生物及其应用
ES2959842T3 (es) 2017-02-21 2024-02-28 Genfit Combinación de un agonista de PPAR con un agonista de FXR
EP3600293A1 (en) 2017-03-30 2020-02-05 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
US20220241376A1 (en) 2019-07-18 2022-08-04 Enyo Pharma Method for decreasing adverse-effects of interferon
MX2022008062A (es) 2020-01-15 2022-07-27 Inst Nat Sante Rech Med Uso del agonista fxr para el tratamiento de una infeccion por el virus de la hepatitis d.
CN111793034B (zh) * 2020-07-24 2021-11-19 华中科技大学 苯并咪唑盐衍生物与制备抗肿瘤药物的应用
KR20230154806A (ko) 2021-01-14 2023-11-09 엔요 파마 Hbv 감염 치료를 위한 fxr 작용제 및 ifn의 상승작용효과
EP4329761A1 (en) 2021-04-28 2024-03-06 ENYO Pharma Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2829765A1 (fr) * 2001-09-14 2003-03-21 Lipha Derives imidazolylalkoxylarylalcanoiques leurs applications en therapeutique
EP2322521B1 (en) 2002-02-06 2013-09-04 Vertex Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of GSK-3
US6949542B2 (en) 2002-02-06 2005-09-27 Hoffman-La Roche Inc. Dihydro-benzo[b][1,4]diazepin-2-one derivatives
EP1646614A4 (en) * 2003-07-01 2008-09-10 Merck & Co Inc OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
CN101479249B (zh) * 2006-06-29 2012-10-10 霍夫曼-拉罗奇有限公司 苯并咪唑衍生物、其制备方法、它们作为fxr激动剂的用途及含有它们的药物制剂

Also Published As

Publication number Publication date
AU2008291148B2 (en) 2011-03-17
WO2009027264A1 (en) 2009-03-05
CN102083799A (zh) 2011-06-01
EP2188263B1 (en) 2012-06-27
CN102083799B (zh) 2013-10-16
TW200916099A (en) 2009-04-16
US7790904B2 (en) 2010-09-07
MX2010002341A (es) 2010-03-22
ES2387230T3 (es) 2012-09-18
PE20090622A1 (es) 2009-05-16
BRPI0815696A2 (pt) 2016-06-21
US20090062356A1 (en) 2009-03-05
JP2010536915A (ja) 2010-12-02
EP2188263A1 (en) 2010-05-26
KR20100051734A (ko) 2010-05-17
JP5204232B2 (ja) 2013-06-05
AU2008291148A1 (en) 2009-03-05
KR101237577B1 (ko) 2013-02-26
CA2697167A1 (en) 2009-03-05
CA2697167C (en) 2013-07-16
CL2008002506A1 (es) 2009-06-12

Similar Documents

Publication Publication Date Title
AR070648A1 (es) Derivados de bencimidazol sustituido
ES2521596T3 (es) Combinación del compuesto GlyT1 con antipsicóticos
ES2524966T3 (es) Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para uso en el tratamiento del cáncer
CR20140548A (es) Derivados de aril-sultamo como moduladores de rorc
ECSP12012293A (es) Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos
CY1117481T1 (el) Φαρμακευτικη συνθεση που περιεχει παραγωγο κινολινης
CY1116120T1 (el) Παραγωγα ιμιδαζοπυριδινης ή ιμιδαζοπυριμιδινης ως αναστολεις φωσφοδιεστερασης 10α
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
NI201400023A (es) Derivados de pirrolopirimidina y purina
AR087328A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
AR072962A1 (es) Derivados de pirimidin-4-ona sustituidos
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
CO6241157A2 (es) "derivados de 6-(pirrolidin-3-il)-1h-pirazolo{3,4-d}pirimidin-4(5h)-ona utiles como inhibidores de pde9"
ECSP11011365A (es) Sales de adición de aminas que contienen grupos hidroxilo y/o carboxílicos con derivados de ácido aminonicotínico como inhibidores de dhodh
CU20110145A7 (es) Derivados de sulfonamida
NZ629025A (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
CR11757A (es) Compuestos de triazina como inhibidores mtor y quinasa pi3
CU20110078A7 (es) Compuestos de carbazol
AR094911A1 (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M₃
UY35320A (es) ?COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2-AMINA SUSTITUIDA CON HETEROARILO?.
CU20080165A7 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
CU20090173A7 (es) Nuevos compuestos heterocíclicos nitrogenados, su preparación y su utilización como medicamentos antibacterianos
AR077534A1 (es) Derivados de isoxazol, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con el receptor gaba aalfa5
AR066605A1 (es) Derivados de heteroarilamida pirimidona

Legal Events

Date Code Title Description
FA Abandonment or withdrawal